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Diospyrin, is a bis-naphthoquinone, which was isolated from Diospyros montana 
Roxb. The objective of this study was to determine the antimycobacterial activity of 
diospyrin (D1) and four of its derivatives (D2, D5, D7 and D17) against the non-pathogenic 
Mycobacterium aurum. The effect of these compounds was determined on growth parameters 
and drug efflux pumping activity.  Diospyrin was shown to be the most active in inhibiting 
the growth of M. aurum whilst D2 was inactive.  D17 was found to have the lowest MIC of < 
0.1 µg/ml, while the MIC of other compounds were found to be as follows: D1= 0.1 µg/ml, 
D5= 0.39 µg/ml, D7= 0.78 µg/ml and D2 =3.13 µg/ml, in order of potency.  The compounds 
were bacteriostatic rather than bactericidal as the MBCs were greater than 50 µg/ml. The 
compounds were potent efflux pump inhibitors as D5 enhanced ciprofloxacin accumulation 
by 160 %, D17 by 58 %, D7 by 41 %, D1 by 37 % when compared with the standard efflux 
pump inhibitor, reserpine, which enhanced accumulation by 51 %.  D2 had no effect on drug 
efflux pumping activity.  The modifications of diospyrin enhanced the activity of D17 and 
D5 by decreasing the MIC and enhancing accumulation of ciprofloxacin, respectively.  In 
contrast, activity decreased significantly for D2 in the growth and accumulation assays.  
Diospyrin and its derivatives are potential antimycobacterial agents and drug efflux 
inhibitors and could be used to enhance the activity of known antimycobacterial agents that 
are actively effluxed from M. tuberculosis. 
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Tuberculosis is one of the most 
infectious diseases at the moment there are 
about 8 million infections a year worldwide, 3 
million are clinical cases and result in 2 
million deaths (Knechel, 2009).  The other 5 
million that are infected are asymptomatic, 
and able to infect other individuals.  Infection 
is via droplets that can remain infective for 
several hours in the air before they are 
inhaled and suitable conditions for growth 
are provided (Palmer  et al., 2002).  The World 
Health Organization (WHO) introduced the 
directly observed treatment system (DOTS) in 
order to ensure compliance to treatment and 
perhaps, lower the incidence of resistance.  
This treatment schedule consists of a 
combination of four anti-TB drugs, isoniazid, 
rifampicin, ethambutol and pyrazinamide 
that are taken over a six to eight month 
period (Scoy and Wilswoske, 1999).  TB 
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treatment is available to the 3 million 
symptomatic individuals and sometimes 
these measures are unsuccessful leading to 
the development of resistance.  Zimbabwe is 
ranked 22nd on the list of 22 high burden TB 
countries in the world and according to the 
World Health Organization’s (WHO Global 
report, 2011), Zimbabwe had an estimated 
71,961 tuberculosis cases in 2007 with an 
estimated incidence rate of 539 cases per 
100,000 populations.  Zimbabwe has the 
second highest mortality TB rate in the world 
and TB-HIV/AIDS co-infection rate is high 
with nearly 79% of new adult TB patients 
testing positive (WHO country profile, 2011).  
HIV infection compromises the immune 
system leading to the activation of the 
replication of mycobacteria harbored by the 
macrophages.  The rapid spread of TB calls 
for decisive action and the need for newer 
antimycobacterial agents (WHO Global TB 
report, 2011). There is need to better 
understand the mechanisms of resistance to 
the currently available drugs and to reduce 
the incidence of drug resistant cases.    Drug 
efflux has been described as an important 
mechanism for intrinsic and acquired drug 
resistance in microbes (da Silva et al. 2011) 
 Plant-derived drugs have been used 
worldwide in clinical medicines for the 
treatment of various diseases.  Plant species 
still serve as a rich source of many novel 
biologically active compounds, as very few 
plant species have been thoroughly 
investigated for their medicinal properties 
(Gautam et al., 2007).  Several plants such as 
Buddleja saligna have been screened for their 
anti-mycobacterial activity (Bamuamba et al., 
2008).  Some plants extracts have been found 
to be active against M. tuberculosis and other 
model mycobacteria such as M. smegmatis 
and M. bovis (Gautam et al., 2007).  
Ethnobotanical information has also shown 
that plants such as the Euclea species are used 
in folk medicine to treat diseases such as TB 
(McGaw et al., 2008).  Many medicinal plants 
produce a variety of compounds of known 
therapeutic properties.  Substances that can 
either inhibit the growth of pathogens or kill 
them and have little or no toxicity to host 
cells are considered good candidates for 
developing new antimicrobial drugs (Woods-
Panzaru, 2009).  With more than 80% of the 
population of developing countries relying 
on traditional medicines, the importance of 
the role of medicinal plants in the health care 
delivery is enormous, particularly for the 
respiratory diseases (Chigora et al., 2007). 
  Phytochemicals could improve the 
activity of existing drugs by acting as efflux 
pump inhibitors and can also reduce the 
occurrence of drug resistant forms of bacteria 
(Stavri et al., 2008).  Efflux pumps are able to 
remove antimicrobials from within the cell 
leaving sub-toxic concentrations (Fernades et 
al., 2003).  Inhibition of efflux pumps makes 
them attractive drug targets.  Instead of  
searching for new antimycobacterial agents, 
efflux pump inhibitors (EPI) can be co-
administered with current antibiotics to 
reduce resistance by allowing the 
accumulation of the drug within the cell 
(Marquez et al., 2005).  The spread of multi-
drug resistant (MDR) strains of bacteria 
necessitates the discovery of new classes of 
antimycobacterials and compounds that 
could inhibit these resistant mechanisms 
(León-Díazet al., 2010).  Diospyrin, a bis-
naphthoquinone (Fig 1) compound, occurring 
in some plants of Ebenaceae family, was first 
shown to possess strong inhibitory activity 
against murine tumor in vivo (Hazra et al., 
1984). Thereafter, several of its semi-synthetic 
derivatives were found to induce significant 
apoptosis in human cancer cell lines 
(Chakrabarty et al., 2005), thereby, indicating 
a strong prospect of this ‘lead’ compound to 
be developed for novel chemotherapeutic 
applications (Das Sarma et al., 2008; Kumar et 
al., 2009).  In fact, diospyrin and its analogues 
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have been observed to inhibit the growth of 
Mycobacterium tuberculosis in culture (Bansal 
et al., 2010).  The present study was 
undertaken to determine the effect of 
synthetically modified diospyrin against 
Mycobacterium aurum, which is considered to 
be a good model for M. tuberculosis due to its 
non-pathogenicity potential and rapid 
growth rate.   M. aurum has the same 
sensitivity profile as M. tuberculosis as their 
fatty acid chains are of similar length which 
plays an important role in susceptibility of 
mycobacteria (Chung et al., 1995).  M. aurum, 
therefore, has been used frequently in drug 
screening where the actual pathogens cannot 
be grown without risk of pathogenesis in 
inappropriate laboratories (Shawar et al., 
1997).  This is the first study on diospyrin and 
its derivatives to explore their application as 
potential drug efflux inhibitors for the 
treatment of tuberculosis. 
 
MATERIALS AND METHODS 
Mycobacteria and Reagents 
Rifampicin, ciprofloxacin, dimethyl 
sulphoxide (DMSO), reserpine, Middlebrook 
7H9 base, agar and casein acid hydrosylate, 
glucose, ethanol, glycine, hydrochloric acid, 
sodium chloride, potassium chloride, 
disodium hydrogen phosphate, sodium 
dihydrogen phosphate, iodonitrotetrazolium 
(INT) and 3-4, 5-dimethylthiazol-2-yl-2, 5-
diphenyltetrazolium bromide (MTT) were 
purchased from Fluka and Sigma-Aldrich 
(Darmstadt, Germany).  M. aurum A+ was a 
kind gift from Professor P. Smith from the 
Department of Pharmacology, University of 
Cape Town, South Africa.  The strain was 
obtained from Institute Pasteur, Paris, France.  
Diospyrin was isolated from the stem bark of 
Diospyros montana Roxb., which was collected 
from Bolangir district, Orissa, India, and the 
voucher specimen was authenticated at the 
Botanical Survey of India, Calcutta.  The 
compound was isolated and purified as 
previously described by Hazra et al. (1984).  
Its structure has been established through 
routine spectroscopic methods, and it was 
reconfirmed to be 2,6’-bis(5-hydroxy-7-
methyl-1,4-naphthoquinone) through total 
synthesis (Yoshida and Mori, 2000, Hazra 
2004).  The four derivatives of diospyrin were 
synthesised, purified and authenticated 
spectroscopically, as described before (Das 
Sarma et al., 2007).  
 
Bacterial strains and growth conditions 
Mycobacterium aurum A+ was grown in 
Middlebrook 7H9 media supplemented with 
casein acid hydrosylate (CAH) and in 
Middlebrook 7H11 solid media at 370C under 
aerobic conditions.  
 
Preparation of media  
Middlebrook (MB) 7H9 broth or MB 7H11 
agar were used for the growth of M. aurum 
A+.  Middlebrook 7H9 and 7H11 media was 
made up with 5.2 g/L Middlebrook 7H9 base 
supplemented with 1 g/L casein acid 
hydrosylate with 15 g/L of agar for the solid 
media. The media components were 
dissolved in boiling water and autoclaved to 
sterilise the media.  The five test compounds 
were all dissolved in DMSO to make stock 
solutions of 5 mg/ml.  A 2.5 mg/ml stock 
solution of rifampicin was also prepared in 
DMSO. A 10 mM stock solution of reserpine 
was prepared in DMSO. 
 
Antimycobacterial susceptibility test by the 
disc diffusion assay  
The agar disk diffusion method was to 
determine if the test compounds were able to 
inhibit the growth of M. aurum as described 
by Suresh et al., (2008) with modifications.  
The test material equivalent to 50 µg, 
dissolved in DMSO was applied on sterile 
paper discs (6 mm diameter, cartridge 
susceptibility discs, Mast Diagnostics, Mast 
Group Ltd, Merseyside, UK).  The discs were 
sterilized and placed in microtitre plates and 
loaded with different volumes of the various 
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stock solutions of the five bis-
naphthquinones.  The compounds were 
dissolved in dimethyl sulfoxide (DMSO) to 
get final concentrations of 50, 25, 12.5 and 
6.25 µg/ml.  Rifampicin was used as the 
positive control at final concentrations of 50, 
5, 0.5, 0.1 µg/ml and DMSO was used as the 
negative control. The filter papers with the 
loaded compounds were dried under an 
airstream to evaporate the solvent.  A 1 x 106 
colony forming units (cfu)/ml dilution of M. 
aurum was mixed with Middlebrook 7H11 at 
a ratio of 1: 20 ml respectively.  The mixture 
was poured and spread on plates.  The dried 
filter paper discs were placed on the surface 
of the solid agar and incubated at 4 °C in a 
refrigerator for two hours to allow diffusion 
of compounds into the agar.   The plates were 
removed from the refrigerator and incubated 
at 37 oC overnight in an incubating shaker 
(Lab Companion, Woburn, Massachusetts, 
USA).  
 
Determination of MICs 
The method used was adopted from McGaw 
et al., (2008) with slight modifications.  
Diospyrin, the four derivatives and 
rifampicin were serially diluted two fold 
from 50 µg/ml with DMSO up to a final 
concentration of 0.1 µg/ml.  Aliquots of 20 µL 
of each of the above compounds were taken 
and added to 80 µL of X 2 Middlebrook 7H9 
supplemented with casein acid hydrosylate 
medium in wells of a 96 well microtitre plate 
in duplicate.  A third row for each serially 
diluted compound was left with no inoculum 
so as to act as the control.  Mycobacterium 
aurum was added to each of the wells in 100 
µL aliquots with the exception of the sterility 
control wells where 200 µL of media was 
added.  The microplate was covered and 
sealed with parafilm before being placed in a 
plastic container lined with absorbent paper 
saturated with sterile water.  The container 
was wrapped in aluminium foil and 
incubated at 37 oC overnight in an incubating 
shaker (Lab Companion, Woburn, 
Massachusetts, USA). Aliquots of 40 µL of 
MTT were added to all the wells and the plate 
was incubated at 37 oC for 1 hour.  The optical 
densities of the wells were read using 
Biokinetics Reader EL350 (Bio-TekTM 
Instruments, Highland Park, Winooski, VT, 
USA) at 550 nm.  The MBCs of the 
compounds were then determined on solid 
Middlebrook 7H11 media according to the 
method by Amsterdam, (1996) with 
modifications.  Aliquots of 25 µL were taken 
from the wells that had no visible growth and 
spread on solid Middlebrook 7H11 using 
glass spreaders.  The plates were then 
incubated overnight and checked for growth 
to determine the MBC of each compound.  
 
Determination of effects on drug efflux 
The accumulation of ciprofloxacin was 
measured according to the method by 
Piddock et al., (1998) with modifications.  M. 
aurum was grown in Middlebrook 7H9 at 37 
oC to OD600 of between 0.5 - 0.7 and harvested 
by centrifugation at 3000 rpm for 10 minutes.  
The bacteria were then re-suspended in 50 
mM sodium phosphate buffer (pH 7.0) at 4 oC 
and made up to 40 mg/ml (dry weight of 
cells).  The cells were placed in a water bath 
set at 37 °C for 15 minutes.  Samples were 
split into sample A and B and maintained at 
the same temperature.  Ciprofloxacin was 
added to both samples to a final 
concentration of 20 mg/L.  Aliquots of 750 µL 
were taken at 0, 1, 5, 10, 15, 30, 45 and 60 
minutes after the addition of ciprofloxacin 
from both sample A and B.  Samples were 
diluted immediately into 750 µL chilled 
sodium phosphate buffer (pH 7.0) on ice and 
centrifuged in a micro centrifuge (Hermle 
Labortechnik, Germany) at 8000 r/min, at 4 
oC for 5 minutes.  The cells were then washed 
with chilled phosphate buffer and 
centrifuged for 5 minutes.  The cell pellet was 
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then suspended in 1.5 ml glycine 
hydrochloride (0.1 mol/L, pH 3.0) for 3 hours 
at 37 oC and centrifuged at 8000 rpm for 10 
minutes.  The supernatant was centrifuged 
for another 5 minutes.  Fluorescence of 
ciprofloxacin in the supernatant was 
determined at an excitation wavelength of 
270 nm and emission wavelength of 479 nm 
using a RF -1501 spectrofluorimeter 
(Shimadzu, Kyoto, Japan).  The active efflux 
of ciprofloxacin was then examined with an 
efflux pump inhibitor, 50 mg/ml stock 
solution in DMSO, which was added to a 
final concentration of  100 µmol/ml but not 
sample B.  Aliquots of 750 µL were removed 
at 5, 15 and 30 minutes after the addition of 
the efflux pump inhibitor reserpine.  To rule 
out interference from the reserpine, the 
fluorescence of diospyrin and the four 
derivatives was also measured same the 
excitation and emission wavelength as 
ciprofloxacin.  The compounds were diluted 
in 3 ml of 0.1 M glycine-HCl, pH 3, up to a 
concentration of 100 µM which was the 
concentration used in the ciprofloxacin 
accumulation assay. 
 
Statistical analysis 
All values have been expressed as mean ± 
standard deviation was evaluated by 
applying Dunnett’s Multiple Comaprison 
Test using Graphpad Prism 5 software® for 
Windows  version 5.03(GraphPad Prism Inc. 
San Diego, CA, USA).  P < 0.05 values or less 
were considered to indicate statistically 
significant difference. 
 
RESULTS 
Assessment of the antimycobacterial activity  
Assessment of the antimycobacterial activity 
of the compounds was conducted using the 
agar disk diffusion method.  Table 1 shows 
the zone of inhibition obtained from when 50 
µg of a compound were loaded onto a filter 
paper disk.  Rifampicin, the standard drug, at 
5 µg/disc was the most active with an 
average diameter of 19.5 mm.  Diospyrin was 
the most active of the test compounds with a 
diameter of 13.5 mm, followed by D17 with 
11.5 mm.  D5 and D7 were the next most 
active with average diameters of 10 and 8 mm 
respectively.  D2 was inactive as it had a 
diameter of 6 mm, the diameter of the 
negative control.  A rifampicin standard 
curve of the zone of inhibition against 
concentration was constructed and used to 
interpolate the concentrations of the test 
compounds that were equivalent to those of 
the standard drug, rifampicin (data not 
shown). 
 
Table 1: Zones of growth inhibition, MIC and MBC values for diospyrin and derivatives 
Compound  Zone of 
inhibition 
(mm) 
Rifampicin 
equivalence 
(µg) 
MIC 
 (µg/ml) 
MBC 
(µg/ml) 
MBC to 
MIC ratio 
D17 12 ± 1*** 2.5 <0.10 >50 >500 
Diospyrin (D1) 14 ± 1*** 3.4 0.10 >50 >500 
D5 10 ± 0*** 1.8 0.39 >50 >128 
D7 8 ± 1* 0.8 0.78 >50 >64 
D2 6 ± 0 - 3.13 >50 >16 
Rifampicin  17± 2*** - 0.20 >50 >250 
DMSO 6± 0 - - - - 
D17- dimethyl ether epoxide, D1- diospyrin, D5- diacetyl, D7- diethyl ether, D2- dimethyl ether MIC- minimum 
inhibitory concentration,  MBC- minimum bactericidal concentration. n= 2 .  The zone of inhibition were determined 
on 7H11 medium at 50, 25, 12.5 and 6.25 µg/ml.  Rifampicin was used as the positive control at final concentrations 
of 50, 5, 0.5, 0.1 µg/ml and DMSO was used as the negative control.  Values are mean + SD for n = 4. * P < 0.05, *** 
P<0.001 
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Determination of MIC and MBC 
In order to determine the effect of the test 
compounds on the growth parameters of M. 
aurum, the microbroth dilution and viable cell 
methods were used.  Table 2 shows that D17 
was the most active compound against M. 
aurum with an MIC of <0.1 µg/ml.  This was 
followed by D1 with an MIC of 0.1 µg/ml.  
Rifampicin had an MIC of 0.2 µg/ml.  The 
results showed that D17 and D1 were actually 
more potent against M. aurum than the 
standard drug.  The MBC of all the test 
compounds and rifampicin were greater than 
50 µg/ml, showing that these compounds 
were bacteriostatic rather than bactericidal.   
 
Table 2: A summary of the effect of diospyrin and 
derivatives on the ciprofloxacin accumulation at 
the 90 minute point 
D5- diacetyl, D17- dimethyl ether epoxide, D7- diethyl 
ether , D1- diospyrin, D2- dimethyl ether; Values are 
mean ± SD for  n=4and are expressed as the percentage 
of the control.  
  
Effects of diospyrin and derivatives on drug 
efflux 
Overexpression of ATP binding cassette 
(ABC) transporters has been proposed as a 
major mechanism contributing to the innate 
drug resistance in Mycobacterium tuberculosis 
and related mycobacteria  (Alekshun et al., 
2007).  The aim of this part of the study was, 
therefore, to determine the effects of 
diospryin and its derivatives, on ATP 
mediated-drug efflux the bacteria species.  
Figure 3 shows the amount of ciprofloxacin 
that accumulated inside M. aurum after 
exposure to the compounds.  Reserpine or the 
test compounds was added at the 30 minute 
time point.  At 35 minutes, there was an 
increase in the amount of CFX in the cells.  
Table 3 shows that the addition of the 
reserpine resulted in an increase of 51% of 
CFX.  Figure 3 shows the effect of the 
derivative, D5, on CFX accumulation in M. 
aurum which resulted in an increase of 160%.  
Three compounds resulted in an increase in 
the amount of ciprofloxacin of 58 %, 41% and 
37% for D17, D7 and diospyrin itself.  The 
derivative, D2, did not have a significant 
effect on the accumulation, with an increase 
of 1% on addition of the compound. In order 
to rule out interference due to the plant 
extracts, their fluorescence was determined 
separately at the same wavelengths and the 
results are shown in Figure 3.  The 
fluorescence of the compounds was found to 
be negligible relative to that of ciprofloxacin 
at the concentrations that were used in the 
assay.  Reserpine was added at an inhibitor 
concentration of 61 ng/ml whilst the 
concentration of ciprofloxacin added to the 
cells was 20 µg/ml. 
 
Table 3: Summary of the nascent fluorescence of 
the compounds used in the ciprofloxacin 
accumulation assay 
Compound  Fluorescence (f.u.) 
Ciprofloxacin 42.7760 
Reserpine 2.8637 
Diospyrin (D1) -0.0809 
D2 -0.0025 
D5 0.0730 
D7 -0.0098 
D17 0.0716 
 
Compound  Effect Percentage (%) 
D5 Enhanced  301 ± 11 *** 
D17 Enhanced  158 ± 7*** 
D7 Enhanced  141 ± 2*** 
D1 Enhanced  137 ± 11*** 
D2 No effect 100 ± 4 
Reserpine  Enhanced  151 ± 2*** 
Control No effect 100 
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Figure 1: Structures of diospyrin and semi-synthetic derivatives.  Diospyrin, D2- dimethyl ether 
derivative, D5- diacetyl derivative, D7- diethyl ether derivative, D17- diepoxide methyl ether 
derivative.  
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Figure 2: Ciprofloxacin accumulation in M. aurum cells after incubation with potential efflux 
pump inhibitors.  The readings were taken at 10 minute intervals. The arrows indicate the time 
point at which the standard or potential inhibitor was added to the reaction. The values are 
mean ± SD for n =4.  R- reserpine, D5- diacetyl, D17- dimethyl ether epoxide, D7- diethyl ether , 
D1- diospyrin, D2- dimethyl ether 
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DISCUSSION 
Natural products continue to play a 
role in the drug discovery and development 
process, and plants are recognized as very 
useful source of highly active 
antimycobacterial metabolites (McGaw et al., 
2008).  Approximately three-quarters of the 
World’s population rely on medicinal plants 
as their primary source of medicine.  Several 
plants with antimycobacterial activity have 
been screened, resulting in the isolation and 
characterization of several active compounds 
(Ignacimuthu and Shanmugam, 2010; Amin et 
al, 2009; León-Díazet al., 2010).  Presently, the 
potential of the natural plant product, 
diospyrin, and its semi-synthetic derivatives 
as antimycobacterial agents was assessed 
against the non-pathogenic model organism, 
Mycobacterium aurum.  The basis for testing 
the antimycobacterial activity was to 
investigate how effective the compounds as 
potential antimycobacterials and as possible 
drug efflux inhibitors.  The differences in the 
zones of inhibitions the ranking in order of 
potency was D1> D17 > D5 > D7 > D2.  Thus, 
diospyrin was the most potent test compound 
and was more active than all its derivatives. 
The dimethyl epoxide derivative, D17 is a 
slightly larger molecule and it has groups 
that could hinder its diffusion into the agar.  
Motility of molecules is influenced by their 
size and shape. However, the MICs of the 
compounds were in the order of D17 > D1 > 
D5 > D7 > D2.  Naphthquinones are 
phytochemicals that have been shown to be 
quite active within cells, as they have been 
found to have anti-bacterial, antiplasmodial 
and anticancer properties (Hazra et al., 2004, 
Lall et al., 2003).  The activity of the 
compounds seems to be based on the 
nucleophilicity of the substituent groups of 
the compounds that are able to complex 
irreversibly with nucleophilic amino acids in 
proteins (Bansal et al., 2010).  The methyl 
ether epoxide diospyrin derivative, D17 has 
the most nucleophillic substituent groups 
with two epoxide groups and a methyl ether 
group.  Epoxide groups have been found to 
be highly reactive, especially when forming 
adducts with macromolecules such as DNA 
and proteins (Dewick, 2002).    The ether 
group is also slightly reactive due to the 
slightly polar oxygen atom that can associate 
with macromolecules as well.  
Naphthoquinones have also been found to 
form Michael adducts with nucleophillic 
molecules (Van der Kooy, 2007, 
Mukanganyama et al., 2010). 
 MIC to MBC ratios that are greater 
than 32 are considered to indicate that the test 
is bacteriostatic rather than bactericidal 
(Cockerill, 1998).  The same has been shown 
to be true for diospyrin against other 
mycobacterial strains such as M. bovis ATCC 
(McGaw et al., 2008) where the MIC to MBC 
ratio of 40 was observed.  Studies of other 
naphthoquinones, such as lapachol and its 
derivatives, against Staphylococcus aureus also 
found the compounds to be bacteriostatic 
rather than bactericidal, as this ratio for drug 
sensitive strain of S. aureus was > 64 µg/ml 
(Perreira et al., 2006).  
Ciprofloxacin (CFX) fluoresces when 
it interacts with its target enzyme, 
topoisomerase II and it is a substrate of 
mycobacterial efflux pumps (Lechner et al., 
2008).  These characteristics are what make 
CFX ideal to monitor the activity of efflux 
pumps.  The activity of efflux pumping 
inhibition in M. aurum was in the order D5 > 
D17> D7> D1 > D2.  The diacetyl derivative 
of diospyrin, D5, enhanced the accumulation 
of CFX the most, at ~200 % of the control.  
The enhancement in CFX accumulation could 
have been as a result of the diospyrin 
derivatives acting as  pseudosubstrates with 
them being effluxed in place of ciprofloxacin.  
The pseudosubstrate mechanism in literature 
has been postulated as one of the possible 
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mechanisms used to efflux pumps in fungi 
(Cannon et al., 2009).  Several compounds 
have been proposed as acting as 
pseudosubstrates of P-glycoprotein 
(Tsujimura et al., 2008).  Thus, the 
concentration of CFX was able to increase 
inside the cell.  This is a mechanism that has 
been proposed in the development of EPIs 
that inhibit the extrusion of fluoroquinolones 
from within bacterial cells (van Bambeke et 
al., 2006).  The other mechanism that could 
account for the increase is that the compound 
was able to interact with the efflux pump and 
inhibit the action of the pumps.  The 
diospyrin pharmacophore is the quinoid 
group that is involved in the formation of the 
Michael adducts (Van der Kooy, 2007).  The 
standard efflux pump inhibitor in this study, 
reserpine, has been found to be involved in 
the uncoupling the attachment of ATP from 
its nucleotide binding site or domain.  
However, the exact mechanism of action of 
how the uncoupling takes place has not been 
elucidated (Garvey and Piddock, 2008).  
To determine the SAR of the 
compounds used in this work, comparisons 
must be made based on the different 
functional groups that are found on 
diospyrin, the parent compound, and those 
found on the derivatives.  The dimethyl ether 
epoxide derivative, D17 had greater activity 
than diospyrin to a significant extent and this 
could be due to the presence of the epoxide 
groups.  The diacetyl derivative, D5, was also 
potent in the efflux pump inhibition assay. 
The diacetyl groups appear to confer better 
activity to the diospyrin parent compound 
against drug efflux activity. The modification 
of diospyrin to dimethyl ether (D2) seems to 
significantly decrease the antimycobacterial 
activity of diospryin as D2 was the least 
active test compound in all the parameters 
tested.   
In summary, our present study 
showed that diospyrin was able to inhibit 
mycobacterial growth and enhanced the 
accumulation of drugs inside the bacteria. 
The naphthoquinone, diospyrin and its semi-
synthetic derivatives, therefore, have 
potential as antimycobacterial agents and 
further modifications could improve activity.  
The derivatives may have the most potential 
as efflux pump inhibitors.  
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